

Increasing the confidence in read-across of chemicals with *new approach methods data*

Ivan Rusyn, MD, PhD

Department of Veterinary Integrative Biosciences

Texas A&M University

Acknowledgements:

Rusyn laboratory (Texas A&M):

- Fabian Grimm
- Sarah Burnett
- Zunwei Chen
- Yu-Syuan Luo

Alex Tropsha and his laboratory
(UNC-Chapel Hill)

Collaborators:

Weihsueh Chiu (Texas A&M University)

Jessica Wignall (ICF International)

Kate Guyton (IARC)

Andy Shapiro (NIEHS)






Collaborators:

Nicole Kleinstreuer (NIEHS)




Grace Patlewicz (EPA)

George Daston (Procter&Gamble)

Matt Martin (Pfizer)



Data on chromatographic "features"




Definitions: Read-across

- **Read-across** is a method of filling a data gap whereby a chemical with existing data values is used to make a prediction for a '*similar*' chemical
- **Target chemical** is a chemical which has a data gap that needs to be filled i.e. the subject of the read-across
- **Source analogue** is a chemical that has relevant data and has been identified as an appropriate analogue for use in a read-across based on *similarity* to the target chemical


	Source chemical	Target chemical
Property	●	○

- Reliable data
○ Missing data



Known to be harmful

Acute toxicity?
→



Predicted to be harmful

Read-across approaches:


- **Analogue** approach (data from a **source** chemical is read across to the **target** chemical)
- **Category** approach (from **multiple** source chemicals to the target chemical)

3 ways to demonstrate “similarity”:

- functional group,
- common precursors, and
- constant pattern in the changes of potency across the group

ECHA RAAF read-across scenarios:

1. **Analogue** approach: Common toxicant causing same effect
2. **Analogue** approach: Same effect caused by different toxicants
3. **Category** approach: Common toxicant causing same effect, effect varies (trend) across members
4. **Category** approach: Same effect caused by different toxicants, effect varies (trend) across members
5. **Category** approach: Common toxicant causing same effect, effect does not vary across members
6. **Category** approach: Same effect caused by different toxicants, effect does not vary across members



March 2017

Read-Across Scenarios: Characteristics of Anchor and Data-Sparse (DS) Chemicals	Inferring Hazard and Dose- Response Relationships for Data-Sparse (DS) Chemicals from Anchor Chemicals	Examples
Anchor and DS chemicals are all metabolized to same toxic metabolites.	Hazard: Assume same Dose-Response: Adjust for pk in metabolite formation	Dyes that metabolize to dimethoxybenzidine
Anchor and DS chemicals have highly similar metabolic activation. Anchor chemicals show same hazards.	Hazard: Assume same Dose-Response: Adjust for pk and bioactivity of metabolites	Various glycol ethers metabolized to alkoxyacids, sets of nitrosoamines
Anchor and DS chemicals have highly similar patterns of upstream biological effect. Anchor chemicals show same hazards.	Hazard: Assume same Dose-Response: Adjust for pk and differences in levels of bioactivity	Dioxin-like compounds (dioxins, furans, co-planar PCBs), PBDEs
Anchor and DS chemicals have similar patterns of biological activity. Anchor chemicals show similar and related but not identical hazards	Hazard: Assume hazard based on upstream testing Dose-Response: Adjust for pk and bioactivity after testing	Sets of <i>ortho</i> -Phthalates, PAHs

National Academies Report [2017]: Using 21st Century Science to Improve Risk-Related Evaluations


Tab. 1: Reasons for the rejection of the use of read-across in disseminated compliance check decisions published on the ECHA website by July 31, 2015

Reason for rejection	No. of cases
Unclear substance identity, not possible to ascertain structural similarity – A significant issue for UVCB substances with a severe impact on large UVCB categories using a combination of read-across and targeted testing	48
Lack of sufficient evidence to substantiate assumptions made within read-across justifications – Including lack of data on analogues provided in dossier	43
Read-across to inappropriate data – For example read-across to a reproductive screening study to address higher tier reproductive and developmental study requirements	5
Lack of scientific plausibility – Disagreement with hypothesis, data not supportive of arguments presented, too much uncertainty – This often combined with the lack of sufficient evidence/information	20

<http://dx.doi.org/10.14573/altex.1601251>

“Nonetheless, since registrants have made extensive use of alternative methods and adaptation possibilities provided in REACH Annexes VII-XI instead of providing data from experimental studies, verification of the compliance of dossiers in the highest tonnage bands will still require sustained effort over the next years. In particular, ***adaptations based on read-across and weight of evidence are often poorly documented and justified, and are not acceptable.***”

Report on the Operation of REACH and CLP 2016



Committee Charge:

- **to provide recommendations on integrating new scientific approaches into risk-based evaluations**

Committee Sponsors:

- US Environmental Protection Agency
- US Food and Drug Administration
- National Institutes of Health (NIEHS and NCATS)

TOXICOLOGY

**GEORGE DASTON
NIGEL GREENE
HEATHER PATISAUL
KRISTI PULLEN
IVAN RUSYN
ROBERT TANGUAY
JAMES TIEDJE
LAUREN ZEISE**

EPIDEMIOLOGY

**JONATHAN SAMET
ESTEBAN BURCHARD
BEATE RITZ
PAOLO VINEIS
MICHELLE WILLIAMS**

EXPOSURE

**MELVIN ANDERSEN
JON ARNOT
JUSTIN TEEGUARDEN**

STATISTICS

**DAVID DUNSON
FRED WRIGHT**

“Exposure scientists, toxicologists, epidemiologists, and other [subject matter experts] need to collaborate closely to ensure that the full potential of 21st century science is realized.”

<http://dels.nas.edu/Report/Using-21st-Century-Science-Improve/24635>

Using 21st Century Science in Decision-Making: Defining the Areas of “Fit for Purpose”

Priority-setting: Can be based on hazard, exposure, or risk


Assessment of mono-constituent chemicals: Can be included in traditional chemical hazard and dose-response assessments of various regulated substances, such as pesticides, drugs, and food additives

“Site-specific” assessments: Can involve selection of geographic sites or chemicals/mixtures at a contaminated site

Assessment of new and complex chemistries: Can involve assessment of green chemistry, new and *complex substances*, and unexpected environmental degradation products of chemicals in commerce


<http://dels.nas.edu/Report/Using-21st-Century-Science-Improve/24635>

Priority-setting




Assessment of mono-constituent chemicals

Animal-Based Approach




Tox21 Concept




<http://dels.nas.edu/Report/Using-21st-Century-Science-Improve/24635>

Assessment of mono-constituent chemicals



“Site-specific” assessments




<http://dels.nas.edu/Report/Using-21st-Century-Science-Improve/24635>

Use of a “Mechanistic Class” for Cancer Hazard ID



International Agency for Research on Cancer (IARC)

Monographs Program
evaluates causes of human
cancer (hazard identification)




- Classes can be defined by a single common agent
 - Dyes metabolized to benzidine
- Mechanistic class can be defined by similar biological activity
 - Vinyl halides; PCBs; Air pollution
- **Mechanistic data alone can be used as a basis for classification**
 - Using Key Characteristics of Carcinogens as an organizing principle


https://monographs.iarc.fr/cards_page/preamble-monographs/

“Read-across” of Haloacetic acids for Cancer Hazard ID


Mono-haloacetic acids



Di-haloacetic acids



Tri-haloacetic acids



- Example from NTP Report on Carcinogens
- Goal: establish carcinogenicity hazard for a chemical class using “new approach data”
- Structural similarity for HAAs is well known
- Variety of *in vivo*, *in vitro*, and *in silico* data, including use of Key Characteristics of Carcinogens to organize mechanistic data
- Challenges:
 - Lack of clear trends, or a common MOAs
 - Conclusions only reached on HAAs metabolized to common moiety that is already “reasonably anticipated to be a human carcinogen”

https://ntp.niehs.nih.gov/ntp/roc/monographs/haafinal_508.pdf

Read-Across in Risk Assessment by US EPA: A “Tiered Surrogate Approach”

Regulatory Toxicology and Pharmacology 63 (2012) 10–19

Contents lists available at SciVerse ScienceDirect

Regulatory Toxicology and Pharmacology

journal homepage: www.elsevier.com/locate/yrtph




Application of computational toxicological approaches in human health risk assessment. I. A tiered surrogate approach


Nina Ching Yi Wang^{a,*}, Q. Jay Zhao^a, Scott C. Wesselkamper^a, Jason C. Lambert^a, Dan Petersen^a, Janet K. Hess-Wilson^b

^a National Center for Environmental Assessment, US Environmental Protection Agency, 26 West Martin Luther King Drive, Cincinnati, OH 45268, United States
^b US Air Force Center for Engineering and the Environment, Technical Division, Restoration Branch, 3515 S. General McMullen, San Antonio, TX 78226, United States


“...the Superfund Health Risk Technical Support Center [may use] available information in an **appendix** and develop a “screening value.” Appendices **receive the same level of internal and external scientific peer review as the PPRTV** documents to ensure their appropriateness within the limitations detailed in the document. Users of screening toxicity values in an appendix to a PPRTV assessment should understand that **there is considerably more uncertainty associated with the derivation of an appendix screening toxicity value** than for a value presented in the body of the assessment.”



Read-Across in Action: Case Study of *n*-Heptane (US EPA PPRTV Program, 2016)



“...the database for continuous exposure to *n*-Heptane **is inappropriate for the derivation of provisional oral toxicity values**. However, information is available for this chemical, [thus] a “**screening value**” [can be derived]”



- **Similarity Context 1:** *n*-Hexane and *n*-Nonane are compounds that have high structural similarity to *n*-Heptane (>84%)
- **Similarity Context 2:** *n*-Nonane is metabolized *in vivo* similarly to *n*-Heptane (higher relative amounts of the 2-and 3-alcohol and γ -valerolactone metabolites formed, compared to the neurotoxic γ -diketone compounds from *n*-Hexane candidate analogue)
- **Similarity Context 3:** *n*-Nonane-induced proliferative forestomach lesions are similar to the lesions observed after oral *n*-Heptane exposure (as compared to unique *n*-Hexane induced neurotoxicity)

N-Nonane Oral 90 day study

Table 5. Incidence of Tissue Lesions^a

Lesion	Dose (mg/kg-day)							
	0		100		1000		5000	
	Mice	Rats	Mice	Rats	Mice	Rats	Mice	Rats
Stomach (nonglandular)—squamous epithelial hyperplasia/hyperkeratosis	0/9	0/10	6/10	8/10	7/8	10/10	8/8	10/11
Proximal Duodenum— inflammation (mild)	0/7	0/10	0/10	0/10	0/10	0/10	0/10	2/10
Rectum—perianal hyperplasia, hyperkeratosis and inflammation	0/9	0/10	0/10	0/10	2/10	5/10	8/10	9/11
Nasal Turbinates—rhinitis	0/9	0/10	0/10	1/9	0/10	7/10	4/10	9/10

^aDodd et al., 2003; C57BL/6 mice; Fischer 344 rats

Screening Subchronic p-RfD = Surrogate POD \div UF_C
 = 3.13 mg/kg-day \div 1,000
 = 3×10^{-3} mg/kg-day
(For n-Hexane!)

Read-Across in Action: Case Study of *p,p'*-DDD (US EPA PPRTV Program, 2017)




United States
Environmental Protection
Agency


EPA/690/R-17/006
FINAL
09-20-2017

Provisional Peer-Reviewed Toxicity Values for
p,p'-Dichlorodiphenyldichloroethane (*p,p'*-DDD)
(CASRN 72-54-8)


Similarity Context	Summary of Findings
Structure and physicochemical properties	<ul style="list-style-type: none"> <i>p,p'</i>-DDD and identified analogues (<i>p,p'</i>-DDT and <i>p,p'</i>-DDE and methoxychlor) demonstrate similarities in basic structural features (chlorinated diphenylalkane structure) <i>p,p'</i>-DDT and <i>p,p'</i>-DDE also share key functional groups (<i>p,p'</i>-chlorine substituents) and physicochemical properties important for bioavailability (lipophilicity and low BCF values) with <i>p,p'</i>-DDD
Toxicokinetics	<ul style="list-style-type: none"> <i>p,p'</i>-DDT is a metabolic precursor of <i>p,p'</i>-DDD and both chemicals show similarities in toxicokinetics (Absorption, Distribution and Metabolism [ADME]) in humans and experimental animal models (preferential partitioning into fat, similar metabolism and excretion pathways and prolonged elimination rates) Other analogues demonstrate differences in ADME in comparison to the target. <i>p,p'</i>-DDE is less metabolically active; methoxychlor is metabolized differently and appears to be less bioaccumulative
Toxicodynamic	<ul style="list-style-type: none"> Consistency and coherence across health effects in experimental animals for non-cancer oral toxicity among the analogues point to putative toxicity targets for <i>p,p'</i>-DDD (primarily liver and reproductive toxicity) Similarities in <i>in vitro</i> bioactivity profiles from ToxCast assays between the target and analogues with respect to cell-specific responses and target gene pathways provide mechanistic plausibility for the liver and reproductive effects associated with this group of chemicals



Combining chemical descriptors and bioassays




Results: QSAR models < Hybrid models < Toxicogenomics models



Chemical-Biological Read-Across (CBRA)


allows visual comparison of multiple compounds



Low et al. (2013) *Chem. Res. Toxicol.* 26(8):1199-208.


Use of connectivity mapping and genomics to support read across

- Test 100s of chemicals in many *in vitro* cells
- Collect high-throughput gene expression data
- Find chemicals that are best “analogues”




DeAbrew et al Tox Sci 151 (2016) 447–461

Alkyl Phenol Case Study



Diaminobenzene Case Study



DeAbrew et al Toxicology 423 (2019) 84–94

US EPA's GenRA v1 – Approach

I. Data

1,778 Chemicals
3,239 Structure descriptors (chm)
820 Bioactivity hitcall (bio)
ToxCast




574 toxicity effects (tox) ToxRefDB

II. Define Local neighborhoods

Use K-means analysis to group chemicals by similarity
Use cluster stability analysis
~ 100 local neighborhoods

III. GenRA

Use GenRA to predict toxicity effects in local neighborhoods
Evaluate impact of structural and/or bioactivity descriptors on prediction
Quantify uncertainty



Slide courtesy of Dr. Grace Patlewicz (US EPA)

Shah et al. Regul Toxicol Pharmacol. 2016; 79:12-24

<https://comptox.epa.gov/dashboard/>

United States Environmental Protection Agency

Home
Advanced Search
Batch Search
Tools
Predictions
Downloads

Copy
Share
Submit Comment
Search all data

Terfenadine
50679-08-8 | DTXSID2023642
Searched by DSSTox Substance Id.

DETAILS
EXECUTIVE SUMMARY
PROPERTIES
ENV. FATE/TRANSPORT
HAZARD
ADME
EXPOSURE
BIOACTIVITY
SIMILAR COMPOUNDS
GENRA (BETA)
RELATED SUBSTANCES
SYNONYMS
LITERATURE
LINKS
COMMENTS

Generalized Read-Across (GenRA)

Step Three: Run GenRA Prediction

Neighbors by: Chem: Morgan Fgprts
Filter by: invivo data
Summary Data Gap Analysis
Group: ToxRef
By: Tox Fingerprint
Generate Data Matrix

Terfenadine
(2R,6S)-Fenpropimorph
Fenbutatin oxide
Volinanserin
Cyproconazole
Cumyluron
Propargite
Benzotrichloride
2-Phenylpropan-1-ol
SSR150106
Fenbuconazole


	Invivo	Invivo	Invivo	Invivo
Terfenadine	11	0	27	0
(2R,6S)-Fenpropimorph	32	277	10	279
Fenbutatin oxide	0	0	12	345
Volinanserin	10	713	22	205
Cyproconazole	14	519	15	408
Cumyluron	0	0	11	177
Propargite	41	519	11	260
Benzotrichloride	17	714	11	63
2-Phenylpropan-1-ol	14	0	9	85
SSR150106	33	0	13	289
Fenbuconazole	34	519	17	345

	Terfenadine	(2R,6S)-Fenpropimorph	Fenbutatin oxide	Volinanserin	Cyproconazole	Cumyluron	Propargite	Benzotrichloride	2-Phenylpropan-1-ol	SSR150106	Fenbuconazole
CHR:Abdominal Cavity											
CHR:Adrenal Gland											
CHR:Artery (General)											
CHR:Auditory Startle Re...											
CHR:Bile duct											
CHR:Blood											
CHR:Blood vessel											
CHR:Body Weight											
CHR:Bone											
CHR:Bone Marrow											
CHR:Brain											
CHR:Bronchus											

Run Read-Across
GenRA
Min+: 0
Min-: 0
Filter:
Similarity Weight:
Download: Filetype

	Terfenadine	(2R,6S)-Fenpropimorph	Fenbutatin oxide	Volinanserin	Cyproconazole	Cumyluron	Propargite	Benzotrichloride	2-Phenylpropan-1-ol	SSR150106	Fenbuconazole
CHR:Adrenal Gland	1.00	0.27	0.19	0.19	0.18	0.18	0.18	0.17	0.17	0.17	0.17
CHR:Artery (General)											
CHR:Auditory Startle Re...											
CHR:Bile duct											
CHR:Blood											
CHR:Blood vessel											

“Exploring drug space with *ChemMaps.com*”



Chemical space: a complex compendium of 1D, 2D and 3D pre-computed molecular descriptors to generate the chemical space in three dimensions

Web interface: an interactive, mouse-based, easy-to-use navigation in any internet browser on mobile or computer platforms

Navigation options: Inspired by Google Maps

DrugMap	DSSToxMap	PFAS
Drugbank Version	DSSTox Release	t
5.1.2, release 2018-12-20	2019-3-09	
~12,000 entries	> 800,000 entries	~ 5



Proposed Applications of ChemMaps:

- Users can search, mine and explore [the] library of drugs as easily as they would look at a city map.
- [Could] open new perspectives for drug repurposing, e.g. by directly visualizing the proximity and structure similarity between two drugs being very close in the drug space.


Borrel et al *Bioinformatics*, 34(21), 01 November 2018, Pages 3773–3775

ToxValue.org

CTV Conditional Toxicity Value

An *In Silico* Approach for Generating Toxicity Values for Chemicals


Animal
toxicity data
↓
“Toxicity
Value”
[Regulatory]
↓
Prediction of
a Regulatory
Value



Toxicity value type	Toxicity value name	Number of cmpds with a toxicity value
Oral exposure non-cancer	Reference Dose (RfD)	671
	No Observed Adverse Effect Level (NOAEL)	487
	Benchmark Dose (BMD)*	137
	Benchmark Dose Lower Level (BMDL)*	137
Oral exposure cancer	Oral Slope Factor (OSF)	302
	Cancer Potency Value (CPV)	225
Inhalation exposure (non-cancer and cancer)	Reference Concentration (RfC)	152
	Inhalation Unit Risk (IUR)	150

Please select a toxicity value of interest.

- ☐ **Select All**
- ☐ CTV Reference Dose (RfD) (Chembench models: 67612 and 70526)
- ☐ CTV Reference Dose (RfD) NO(A)EL (Chembench models: 67624 and 66226)
- ☐ CTV Reference Dose (RfD) BMD (Chembench models: 67570 and 70508)
- ☐ CTV Reference Dose (RfD) BMDL (Chembench models: 67582 and 66214)
- ☐ CTV Reference Concentration (RfC) (Chembench models: 67600 and 70520)
- ☐ CTV Oral Slope Factor (OSF) (Chembench models: 67588 and 70514)
- ☐ CTV Cancer Potency Value (CPV) (Chembench models: 67534 and 70490)
- ☐ CTV Inhalation Unit Risk (IUR) (Chembench models: 67546 and 70496)




Read-Across Example Using ToxValue.org


Diethylene glycol ethers (Di EGEs)

Chemical


Diethylene glycol ethyl ether
(DGEE, CAS 111-90-0)



Diethylene glycol monobutyl ether (DEGBE,
CAS 112-34-5)



Diethylene glycol hexyl ether
(DGHE, CAS No. 112-59-4)



Diethylene glycol propyl ether
(DGPE, CAS 6881-94-3)



Critical No Effect Level

NOAEL: 167 mg/kg-day based
on kidney and liver effects in
pigs

Dose	Incidence
0	0/3
167	0/3
500	1/2
1117	1/1

NOAEL: 50 mg/kg-day for
anemia in rats

Dose	#	Mean	SD
0	10	9.27	0.35
50	10	9.13	0.22
250	10	8.94	0.34
1000	10	8.53	0.31



?

50 mg/kg-day



167 mg/kg-day

?





50 mg/kg-day



167 mg/kg-day

Read-Across Example Using ToxValue.org

Diethylene glycol ethers (Di EGEs)


Chemical			
<p>Diethylene glycol ethyl ether (DGEE, CAS 111-90-0)</p> 	<p>Diethylene glycol monobutyl ether (DEGBE, CAS 112-34-5)</p> 	<p>Diethylene glycol hexyl ether (DGHE, CAS No. 112-59-4)</p> 	<p>Diethylene glycol propyl ether (DGPE, CAS 6881-94-3)</p> 
<p>NOAEL: 167 mg/kg-day based on kidney and liver effects in pigs</p> <p>BMD 443 mg/kg-day BMDL 45.2 mg/kg-day</p>	<p>NOAEL: 50 mg/kg-day for anemia in rats</p> <p>BMD 222 mg/kg-day BMDL 81.4 mg/kg-day</p>	<p>?</p> <p>50 mg/kg-day</p> <p>↕</p> <p>167 mg/kg-day</p>	<p>?</p> <p>50 mg/kg-day</p> <p>↕</p> <p>167 mg/kg-day</p>

Critical Point of Departure



ToxValue.org Output

Diethylene glycol hexyl ether
(DGHE, CAS No. 112-59-4)



Chemical name	Model Name	Unit	Prediction	Lower 95%*	Upper 95%*	Appl Domain*
C6E2	CTV Reference Dose (RfD) BMD	-Log ₁₀ Mol/(kg·day)	3.36	1.36	5.30	-0.453
		mg/(kg·day)	83.2	0.960	8.29e+3	
	CTV Reference Dose (RfD) BMDL	-Log ₁₀ Mol/(kg·day)	3.69	1.91	5.41	-0.453
		mg/(kg·day)	38.6	0.739	2.33e+3	

Z-score output: Distance from **your chemical** to the **nearest chemical** in training set **compared** to the average nearest-neighbor-distances in the training set

- 0 = same distance as average distances in the training set
- >0 = your chemical is at a further distance than average distances in the training set
- <0 = your chemical is at a closer distance than average distances in the training set


Use $Z > 1$ as a conservative cut-off for applicability, $Z > 3$ as a less-restrictive cut-off (to define anything < cut-off as within AD of model).

Read-Across Example Using ToxValue.org

Diethylene glycol ethers (Di EGEs)

Critical Point of Departure

Diethylene glycol ethyl ether
(DGEE, CAS 111-90-0)



NOAEL: 167 mg/kg-day based
on kidney and liver effects in
pigs

BMD 443 mg/kg-day
BMDL 45.2 mg/kg-day

Diethylene glycol
monobutyl ether (DEGBE,
CAS 112-34-5)






NOAEL: 50 mg/kg-day for
anemia in rats



BMD 222 mg/kg-day
BMDL 81.4 mg/kg-day

Chemical

Diethylene glycol hexyl ether
(DGHE, CAS No. 112-59-4)



Diethylene glycol propyl ether
(DGPE, CAS 6881-94-3)



Reflections on single-chemical read-across

- Metabolism is often easiest way to define a “class”
- Common mechanisms have worked for a few well-established classes (dioxins, PCBs, PAHs, etc.), but may be more difficult to generalize to other “classes” (e.g., HAAs)
- “Key characteristics” approach may be helpful to organize mechanistic data
- Decision-context-specific questions
 - Hazard or dose-response?
 - Do we need an “-icity”?
 - Do we need to bring in other components such as physical-chemical properties, persistence, bioaccumulation?

Sufficient Similarity Challenge in Read-Across: ***From Case Studies to Application***

- Defining “sufficient”: Depends on who (which agency) you ask...
- Defining “similarity”: It is clear that structure-based similarity alone is insufficient, if you ask the regulators (especially in Europe)
- So if one’s “sufficient similarity” argument is not accepted, what then?
- Are “case studies” the way forward? Yes and no, because some regulators are very impatient and deem “case studies” to be just another “delay tactic” by the industry...
- There are no easy answers but there is no alternative to more work in this area – publication of “case studies” is a path to acceptance